Although bioluminescence imaging (BLI) shows promise for monitoring tumor burden in animal models of cancer, these analyses remain mostly qualitative. Here we describe a method for bioluminescence imaging to obtain a semi-quantitative analysis of tumor burden and treatment response. This method is based on the calculation of a luminoscore, a value that allows comparisons of two animals from the same or different experiments. Current BLI instruments enable the calculation of this luminoscore, which relies mainly on the acquisition conditions (back and front acquisitions) and the drawing of the region of interest (manual markup around the mouse). Using two previously described mouse lymphoma models based on cell engraftment, we show that the luminoscore method can serve as a noninvasive way to verify successful tumor cell inoculation, monitor tumor burden, and evaluate the effects of in situ cancer treatment (CpG-DNA). Finally, we show that this method suits different experimental designs. We suggest that this method be used for early estimates of treatment response in preclinical small-animal studies.
Introduction
Early tumor cell detection remains a challenge and is crucial for enhancing cancer treatment efficacy. In vivo bioluminescence imaging (BLI) is a very sensitive, noninvasive optical technique, widely used for monitoring tumors in small animals. Firefly luciferase-expressing cells are commonly used for such experiments 1, 2 . This oxygenase oxidizes D-luciferin with molecular oxygen but requires two cofactors -Mg 2+ and adenosine triphosphate 3 . Firefly luciferase is more suitable for in vivo imaging than renilla luciferase 4 because its quantum yield is higher.
The oxidized substrate -oxyluciferin -spontaneously emits a photon to return to its fundamental state and then becomes inactive. The emitted photons have a maximum wavelength around 530 nm. A high-sensitivity camera can detect the luminescent photons from the inside of a small animal and provide images that make it possible to locate tumor cells.
The ability to quantify tumor burden accurately by photon counts could serve as a powerful and sensitive tool for quantifying treatment efficacy. Because treatment effects can be detected sooner, this sensitivity might make it possible to determine the exact moment at which a treatment becomes effective.
Absolute quantification of total emitted photons is very complex. The number of photons gathered depends on the depth of the tumor and on the organs the photons are emitted through. Correction coefficients based on tissue absorption coefficients can be calculated 5 , but the absolute quantification of tumor cell numbers requires knowing the number of photons emitted by each tumor cell. Moreover, luciferase expression, like that of many reporter genes (e.g., fluorescent proteins) is not homogeneous, even in a cell population derived from a single clone 6 . The number of luciferase proteins in cells cannot be calculated exactly. The establishment of standardized experimental conditions thus appears crucial for a reliable semi-quantitative analysis.
We applied the luminoscore method to two different mouse lymphoma models 7, 8, 9 each of these orthotopic models, the treatment is administered in situ, seven days after the tumor inoculation for PIOL and when the tumor has reached 0.5 to 0.7 cm in its largest diameter for SCL.
We used the luminoscore method to monitor the effects of in situ CpG therapy, previously shown to be effective 7, 10, 11 . CpG is an oligonucleotide sequence and a ligand of TLR9, which in turn is an intracellular receptor expressed by numerous cells of the immune system, including dendritic cells, B lymphocytes, monocytes, and natural killer cells. CpG-DNA is a 20-mer DNA sequence that contains the CpG (CG) immunostimulatory motif; the control (ODN-control) is the same 20-mer DNA sequence, except that the immunostimulatory CG sequence is inverted (GC). TLR9 engagement in the murine lymphoma we are studying induces apoptosis 10 , activates the immune system 12 , and thereby significantly reduces tumor burden 7, 11 .
Here we describe a standardized method for quantifying tumor burden and treatment response through bioluminescent images. This method relies on different aspects of the imaging procedure, from acquisition to analysis, to optimize reliability, reproducibility, non-user dependence, and statistical significance. A bioluminescence quantification index is attributed to each mouse; this value, which we call a luminoscore, can be compared not only between animals but also between experiments.
In this work, we focus on the bioluminescence imaging procedure as well as the image quantification by the luminoscore method. We show the effectiveness of this method for verifying the injection, monitoring tumor burden, and assessing the efficacy of in situ cancer treatment. Each of these points is illustrated in representative results from experiments using different mouse models to highlight the adaptability of the luminoscore method.
Cell Preparation
1. Grow mouse B lymphoma cell line A20.IIA-luc2 in RPMI-1640 Glutamax medium supplemented with 10% fetal calf serum, 100 µg/ml penicillin, 100 µg/ml streptomycin, 10 mM sodium pyruvate, 50 µM 2-mercaptoethanol, and 0.50 mg/ml hygromycin B. 2. Maintain cell culture at 37 °C, 5% CO 2 and change medium every two to three days. Harvest 5 ml of the cell suspension with a pipette one day after changing the medium. 3. Spin cells at 300 × g for 10 min and suspend the cells in 3 ml sterile phosphate-buffered saline (PBS). Repeat this step twice to wash the cells. . Suspend the cell pellet (from step 1.5)) in the volume of sterile PBS 1x calculated in the previous sentence. Cell suspension A is to be used in the SCL model (in vivo injected volume is 100 µl: 5 x 10 6 cells).
7. Pipette 10 µl of cell suspension A and add 90 µl of sterile PBS in a 1.5 ml tube to obtain 100 µl of cell suspension B at 5 x 10 6 cells per ml.
Cell suspension B is to be used in the PIOL model (in vivo injected volume is 2 µl: 1 x 10 4 cells).
Luciferin
1. Dilute 1 g of D-luciferin potassium salt powder in 30 ml of sterile PBS 1x in a 50-ml tube and shake for a few seconds to dissolve the aggregates. NOTE: Because luciferin is light-sensitive, prepare 500 µl aliquots in dark 1.5-ml microcentrifuge tubes. 2. Store the aliquots at -20 °C.
NOTE: The aliquots can be stored for several months. After thawing, the aliquots must not be stored for more than 1 day at + 4 °C. Freezing-thawing cycles are preferable to storage at 4 °C. 3. Inject 100 µl of D-luciferin potassium salt solution intraperitoneally for each imaging assay.
NOTE: This solution corresponds to 3.3 mg per mouse for a dose of 150 mg/kg.
Anesthetic Mixture and Anesthetization
1. Prepare an anesthetic solution by mixing ketamine 120 mg/kg and xylazine 6 mg/kg in sterile PBS 1x. 2. Inject 60 µl of anesthetic mixture intraperitoneally for each imaging assay with a 25 G needle. For surgery (with the PIOL or SCL model), inject 80 µl of the mixture to obtain a deeper anesthesia. Put the mouse back in its cage. 3. When the mouse appears immobile, remove it from its cage and gently squeeze the mouse's leg between fingers. If the mouse reacts with an escape reflex, wait several min. Repeat the action until the mouse does not react, which confirms satisfactory anesthetization. 4. Place the mouse on a warming plate or under a warming light. 5. Apply eye ointment to avoid eye dryness during anesthetization for the imaging assay or for SCL surgery. Apply the eye ointment after surgery for the PIOL model.
Surgery and Cell Inoculation
NOTE: Perform all surgical procedures on a warming plate or under a warming light, in a type 1 microbiological safety cabinet in an animal biosafety level 2 facility. All surgical tools used in this section were autoclaved before use.
Subcutaneous Lymphoma Model:
1. Prepare 100 µl of the cell suspension obtained in step 1.6 in a 1-ml syringe with a 25 G needle. Gently squeeze the mouse skin on the flank between fingers, at the injection site. Insert the needle exactly into the skin fold. To ensure subcutaneous injection, do not place the needle deep into the tissue. 1. Inject the cells into the skinfold. Observe whether a little liquid ball appears under the skin to confirm that the injection was performed correctly.
PIOL model:
NOTE: This procedure requires 2 operators, referred to here as operator 1 and operator 2. 
Bioluminescence Imaging -Day 0
NOTE: All products injected into the mouse must be at RT before injection. After the tumor cells have been inoculated, and while the animal is still anesthetized, proceed to these steps for the imaging.
1. Turn on the imager and open the acquisition software. Initialize the camera, the stages, and the lenses by clicking on the "Initialize" button. The initialization will take 10 to 15 min to be complete. 2. Inject 100 µl of D-luciferin potassium salt solution intraperitoneally with a 25 G needle. Do not administer it intravenously. If intravenous administration is required for any reason, the D-luciferin sodium salt must be used rather than D-luciferin potassium salt. NOTE: Luciferin is the excess reactant at this concentration; therefore the bioluminescence signal reaches a plateau after 3 to 7 min and persists for more than 30 min. 3. 10 min after D-luciferin injection 13 , place the subject mouse in the imager. Place the mouse in its natural position, its back towards the camera, in as flat a position as possible. This position is natural and easily reproducible. 4. Tick the auto-exposure feature, and click on Acquire to acquire the back (posterior) image of the animal, with the auto-exposure feature.
NOTE: The auto-exposure feature optimizes exposure time by calculating it from a 1-sec exposure image. If the mouse's bioluminescence signal is negative or very low, the optimal exposure time might be automatically set to more than 20 min. In this case, an exposure time of 8 to 10 min may be a good compromise. Exposure time may be set manually, but the images must not contain saturated pixels. 5. Turn the mouse over to expose the front of the mouse to the camera. Try to flatten the mouse and spread its anterior limbs so that they do not block the chest. 6. Acquire a front image of the animal. Verify that the auto-exposure checkbox is still ticked and click again on the "Acquire" button. NOTE: The front image can be acquired before the back image and vice versa. The exposure time of front and back images can be different depending on the relative intensity of each side of the mouse. It is calculated automatically when using the auto-exposure feature. Quantification uses only the photon flux (photons per sec) and does not depend on exposure time. 7. Place the mouse on a warming plate or under a warming light until it recovers from the anesthetic and then place it back in its cage. 
Monitoring Tumor Burden and Treatment Response
The luminoscore is also a powerful tool for studying tumor growth and treatment efficacy. Figure 2A shows representative images of the monitoring of tumor growth in the control and the CpG treated PIOL groups. The mice were inoculated with 1 x 10 4 tumor cells each, and treatment was administered in situ on Day 7. The images show that after a sufficient time (28 days), metastases began to appear in the control group. Although the primary tumor did not appear sensitive to treatment, fewer metastases were observed in the CpG-treated group ( Table 1) . The quantitative analysis of the tumor burden in each group ( Figure 2B) shows that CpG slowed tumor development, producing a statistically significant difference between the treated and the control group after 28 days (non-parametric two-tailed Mann-Whitney test p = 0.0079). Nonetheless, the tumors still grew in the treated mice, and none of them survived (data not shown). This finding is consistent with previous reports: CpG has no significant effects on primary ocular tumors As seen on the dot plot, the effect of CpG on the luminoscore is significant on day 28. In those two groups, this method made it possible to monitor tumor burden and to measure the slight but significant (p = 0.0079) effects of CpG-DNA, which could have not been detected by images alone. Please click here to view a larger version of this figure. The luminoscore method is not limited to a single type of mouse model. Figure 3 shows that it can be adapted to different mouse models. In the SCL model, two tumors are grafted on each side of the mouse. The treatment is administered in situ to a single side on Day 0, and the contralateral tumor serves as its control ( Figure 3A) . Therefore, two ROI were drawn per mouse: one for each side (Figure 3C) . The ratio between the luminoscore on the treated and control sides describes the relative course of each tumor. This ratio was set to 1 on Day 0, when the treatment was administered. We observed a significant decrease in this ratio 13 days after treatment administration (Figure 3D ; non-parametric two-tailed Mann-Whitney test p = 0.004). This decrease reveals that the treated-side tumor has been resorbed, as shown on the representative bioluminescence images ( Figure 3B) . The ratio between the luminoscores of the CpG-treated or ODN-control side and the PBS control side is an index that reflects the relative growth of each tumor within the same animal. This ratio was set to 1 on day 0. On day 13, the ratio of the CpG-treated group had decreased significantly (p = 0.004), revealing inhibition of tumor growth by in situ administration of CpG-DNA. Please click here to view a larger version of this figure.
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Discussion
Light absorption by organs and tissues remains a limitation of bioluminescence imaging, although this limitation is intrinsic to any optical imaging modality. In the context of our approach, the effects of anatomic structures on the luminoscore are expected to have low variability provided that the studies are performed in a given model (location and mouse strand), allowing then comparisons. Bioluminescence does not need excitation light and thus is more adapted to whole body in vivo imaging than fluorescence.
Spatial resolution is also a limitation of bioluminescence imaging, and precise location of the organ from which bioluminescence photons are emitted remains difficult. However, good knowledge of the model can help in the qualitative location of the tumor sites. The only output in this bioluminescence-based method is the luminoscore. Location does not influence the luminoscore because the manual mark-up Region of Interest (ROI) covers the whole mouse. Finally, firefly luciferase requires oxygen. Accordingly, bioluminescence imaging usually underestimates necrotic tumors. Once again, a good knowledge of this aspect of the model is required.
In this paper, we are not aiming at assessing the efficacy of CpG as an anti-tumor drug (which has already been demonstrated 7, 9, 11 ) but to describe a method allowing comparison of bioluminescence datasets. We indeed describe a method to quantify tumor burden intended to help standardize the acquisition protocol for comparing different assays in different places at different times and that does not require computer calculations. To ensure reproducibility and correct photon flux quantification, the imaging device must be calibrated with a light reference for home-made devices or as recommended by the provider for commercial devices.
Our protocol requires careful attention to several critical points: (i) First, the quality of the mouse anesthesia is crucial for obtaining clear images, especially in cases with long exposure times. (ii) The quantification unit must be always be the photon flux because radiance depends on the surface area of each mouse and might be irrelevant for comparing different mice. (iii) The bioluminescence images must not contain saturated pixels, because these would bias the luminoscore. (iv) Back and front acquisition are required to collect all photons emitted from the tumor site (i.e., front acquisition may not necessarily detect photons from the back of the tumor). Various different ROI drawings were tested during the Copyright © 2016 Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License July 2016 | 113 | e53609 | Page 8 of 9 development of the luminoscore method. Only the manual mark-up yielded satisfactory results that are more likely to be statistically significant (data not shown).
Inoue et al. recommend a luciferin dose of 75 mg/kg 13 . By using a dose of 150 mg/kg instead, the timing of imaging after the luciferin administration remains unchanged and we ensure that the plateau lasts throughout a long exposure acquisition. Luciferin must be the excess reactant throughout the acquisition process. Depending on the model, the region of interest can be adapted, as we showed in the SCL model where we drew two ROI per animal. In the SCL model, the treatment is injected when the tumor reaches 0.5 cm in its largest diameter to limit variability of engraftment. Depending on the mice, the tumor might have grown differently. To standardize and compare mice, we decided to use a ratio between treated and non-treated side that reveals the relative growth of both flanks tumors.
If no signal is observed from an injected mouse expected to be positive, either (i) the number of cells is very low and the signal is below the detection threshold; or (ii) the mouse lacks oxygen and requires immediate care.
Several of the quantitative bioluminescence analyses described by various authors require complex calculations and instruments (e.g., 3D bioluminescence tomography) to approach the absolute quantification of emitted bioluminescence photons 5, 15 . There is no consensus on a method for quantifying bioluminescence reproducibly, especially in tumor models, with a 2D bioluminescence imager. Our aim was to standardize the image acquisition protocol to limit user-dependence.
The injection of CpG in situ after tumor inoculation reduced tumor burden in both models. The luminoscore method can serve as a tool to monitor tumor burden in other models of tumor immunotherapies. Monitoring tumor burden provides a noninvasive method that can improve our understanding of tumor growth and metastasizing mechanisms without interfering with the tumor microenvironment. The identification of animals that do and do not respond to treatment with this method is reinforced by the verification of successful tumor cell injection at the beginning of the experiment.
We here showed the adaptability of the luminoscore method in a SCL model using A20.IIA-luc2 cells. However, this method can be adapted to any other tumor model using other cell lines provided that they express luciferase, or in the context of T-cell studies (tumor specific cytotoxic Tcells, regulatory T-cells, etc.). The monitoring of in vivo gene transfer in the context of gene therapy of rare disease could also be done using the luminoscore method.
Finally the data shows that the bioluminescence-based luminoscore method enables comparisons between experiments, offers flexibility and adaptability to specific experimental needs, and is a useful tool for noninvasive longitudinal preclinical studies.
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